Screener
Adaptive Biotechnologies ADPT Immune Medicine Business — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Adaptive Biotechnologies’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:31 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-076902
There have been no changes in the carrying amount of goodwill since its recognition in 2015. In conjunction with our organizational realignment in 2024, we allocated goodwill among our two reporting units using a relative fair value approach. Goodwill allocated to the MRD and Immune Medicine reporting units as of December 31, 2025 was $96.4 million and $22.6 million, respectively.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Adaptive Biotechnologies's immune medicine business — goodwill?
- Adaptive Biotechnologies (ADPT) reported immune medicine business — goodwill of $22.6M in Q4 2025.
- What does immune medicine business — goodwill mean?
- This metric represents the intangible asset value recorded by the Immune Medicine Business segment following an acquisition, reflecting the premium paid over the fair value of net identifiable assets. It serves as an indicator of the segment's historical growth through acquisitions and potential future impairment risks.
Ask your AI about Adaptive Biotechnologies's immune medicine business — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude